Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Phosphate Therapeutics appoints Dr Sandy Eisen to its Board as a Non-Executive Director

3 Jun 2013

Phosphate Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces the recent appointment of Dr Sandy Eisen to its Board as a Non-Executive Director, effective from May 2013. With principal funding from its investment partner Inventages, Phosphate Therapeutics is currently progressing PT20 – a novel phosphate binder to treat hyperphosphataemia associated with end-stage renal disease – towards pivotal clinical trials through an exclusive agreement with Shield Therapeutics. PT20 was licensed from MRC Technology in 2012.

Dr Eisen has 24 years of pharmaceutical regulation and commercial pharmaceutical medicine experience, having worked in several senior government positions as an EU and UK regulator and from 2006 – 2011 working as the Chief Medical Officer for Teva Pharmaceuticals Europe. He brings a deep knowledge of regulatory requirements and drug development issues to the Board of Phosphate Therapeutics.

Dr Eisen graduated from Cambridge University as a physician after studying clinical medicine at St Bartholomew’s Hospital Medical School in London. He also holds a BA and MBA from Cambridge as well as postgraduate medical qualifications in both Surgery (FRCS England) and Pharmaceutical Medicine (Diploma in Pharmaceutical Medicine, RCP/FPM London).

Commenting on the appointment Carl Sterritt, Chief Executive Officer of Phosphate Therapeutics, said: “I am delighted to see Sandy joining the Board of Phosphate Therapeutics. I am sure his wealth of experience in new drug and new biological applications, clinical trials and drug safety will prove most valuable to the ongoing development of PT20, our lead asset.

Back to news